Disease · MONDO_0006804
Comparisons in its trials11
Comparisons Trial comparisons calculated in the trials shown here, most participants first. A comparison in one of these trials does not always compare a treatment for the disease, so read the two groups.
1 to 11 of 11
Download this page as JSON| Comparison | Group 1, with the outcome | Group 2, with the outcome | Participants | Trial | Source |
|---|---|---|---|---|---|
| Arm 1 (Nab-Paclitaxel + Bevacizumab - AC+PEG-G)) vs Arm 2/3 (Nab-Paclitaxel/AC+PEG-G)): Event-free Survival | 20 of 98 | 24 of 113 | 211 | NCT00856492 | Trial comparisons |
| Arm 1 (Nab-Paclitaxel + Bevacizumab - AC+PEG-G)) vs Arm 2/3 (Nab-Paclitaxel/AC+PEG-G)): Number of Patients With Pathological Complete Response Rate | 35 of 98 | 24 of 113 | 211 | NCT00856492 | Trial comparisons |
| Neoadjuvant Chemo Followed by Surgery & High-dose Chemo With PSC Rescue vs High-dose Chemo With Rescue: deaths from any cause | 10 of 14 | 14 of 27 | 41 | NCT00003042 | Trial comparisons |
| Neoadjuvant Chemo Followed by Surgery & High-dose Chemo With PSC Rescue vs High-dose Chemo With Rescue: serious adverse events | 0 of 14 | 2 of 27 | 41 | NCT00003042 | Trial comparisons |
| Part A: Afatinib Once Daily (OD). vs Part B: Afatinib+V (Vinorelbine).: serious adverse events | 12 of 26 | 4 of 10 | 36 | NCT01325428 | Trial comparisons |
| Arm A: Eribulin followed by AC vs Arm B: AC followed by Eribulin: deaths from any cause | 1 of 16 | 0 of 6 | 22 | NCT02623972 | Trial comparisons |
| Arm A: Eribulin followed by AC vs Arm B: AC followed by Eribulin: serious adverse events | 5 of 16 | 1 of 6 | 22 | NCT02623972 | Trial comparisons |
| HER2-negative, Including TNBC or HR-positive vs HER2-positive, Independent of HR Status: Number of Participants Who Had a Pathological Complete Response (pCR) | 0 of 4 | 3 of 4 | 8 | NCT03742986 | Trial comparisons |
| HER2-negative, Including TNBC or HR-positive vs HER2-positive, Independent of HR Status: Number of Participants Who Had a Pathological Complete Response (pCR) | 1 of 4 | 3 of 4 | 8 | NCT03742986 | Trial comparisons |
| HER2-negative, Including TNBC or HR-positive vs HER2-positive, Independent of HR Status: deaths from any cause | 0 of 4 | 0 of 4 | 8 | NCT03742986 | Trial comparisons |
| HER2-negative, Including TNBC or HR-positive vs HER2-positive, Independent of HR Status: serious adverse events | 1 of 4 | 3 of 4 | 8 | NCT03742986 | Trial comparisons |
diseases-2026-09-18-0.1.0
Sources 6
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ChEMBL, through Open TargetsCC BY-SA 3.0
- ClinicalTrials.govNo license stated
- NLM's MeSHNLM's terms
- Open TargetsCC0 1.0
- PubMedNLM's terms
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- ClinicalTrials.govnone stated
- NLM's MeSHNLM's
- Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- PubMedNLM's terms
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this list from software.
Twenty rows a page, as JSON. No key.
GET https://conductscience.org/api/diseases/v1/MONDO_0006804/comparisons